The Light House

Lighthouse Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing precision medicine approaches for degenerative and inflammatory disorders. The company's lead program, LHP588, is a small molecule protease inhibitor targeting Porphyromonas gingivalis, a specific infectious pathogen associated with the progression of Alzheimer's disease and other chronic conditions. Lighthouse acquired its core portfolio of gingipain inhibitors from Quince Therapeutics (formerly Cortexyme) in early 2023, following the latter's strategic pivot. The company is currently advancing its lead asset into Phase 2 clinical trials to validate its treatment paradigm for cognitive decline and other systemic inflammatory diseases.